ADXS - Advaxis, Inc.
Previous close
0.02
0 0%
Share volume: 2,004
Last Updated: Wed 28 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.02
0.00
0.00%
Fundamental analysis
24%
Profitability
16%
Dept financing
5%
Liquidity
75%
Performance
25%
Performance
5 Days
0 0%
1 Month
0 0%
3 Months
-92.00%
6 Months
-97.68%
1 Year
-98.18%
2 Year
-99.37%
Key data
Stock price
$0.02
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.00 - $1.49
52 WEEK CHANGE
-$0.98
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Kenneth Berlin
Region: US
Website: https://www.advaxis.com/
Employees: 45
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.advaxis.com/
Employees: 45
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
advaxis (nasdaq: adxs) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. the advaxis technology, using bioengineered live attenuated bacteria, listeria monocytogenes (lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Recent news